Endocrine Abstracts

Introduction: Dopamine agonists (DA) are first-line treatment for prolactinomas and effectively control hyperprolactinemia in most patients. However, side effects may negatively impact health-related quality of life; and post-withdrawal remission rates are low, resulting in prolonged DA treatment.Methods: Dutch multicenter prospective observational cohort study mapping standard care for 316 prolactinoma patients. Baseline clinical characteristics and tre...

Introduction: Increased insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly are associated with clinical and radiological osteoarthritis (OA). We aimed to elucidate whether serum IGF-1 levels differ in patients with primary OA as compared to healthy controls and whether genetic variants known to affect serum IGF-1 levels are also associated with primary OA.Methods: Patients from the GARP study with familial generalized OA (n=...

Introduction: Patients with prolactinomas suffer from a wide range of symptoms, of which the effect on health-related quality of life (HR-QoL) needs further investigation. Moreover, the first-line treatment for patients with prolactinomas, dopamine agonists (DAs), albeit being effective in lowering prolactin levels, might further hamper HR-QoL due to side effects. To assess the impact of symptoms and treatment modality on HR-QoL, a cohort of patients with prolactinoma was cros...

Objective: Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess results in both reversible and irreversible damage to the skeleton, and includes increased vertebral fracture (VF) risk in the presence of normal BMD. The prevalence of VFs is approximately 60% in controlled acromegaly patients, and these VFs can progress during short-term follow-up. We aimed to identify the course of VFs and their associated risk factors in a cohort of acromegaly patients in long-t...

Purpose : To assess the utility of (18F)fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging (FET-PET/MRICR) in patients with difficult-to-localize prolactinoma to inform clinical decision making and treatment planning.Methods: Retrospective cohort study of 17 consecutive patients with difficult-to-localize prolactinoma undergoing FET-PET/MRICR between October 2020 and Amgust 2022 for either (1) additional inform...